Definium Therapeutics (NASDAQ:DFTX) Rating Increased to Strong-Buy at Jefferies Financial Group

Definium Therapeutics (NASDAQ:DFTX) was upgraded by equities researchers at Jefferies Financial Group to a “strong-buy” rating in a research note issued to investors on Thursday, Marketbeat reports.

Several other equities analysts have also commented on DFTX. Lifesci Capital raised Definium Therapeutics to a “strong-buy” rating in a report on Tuesday, October 14th. Robert W. Baird set a $37.00 price objective on Definium Therapeutics in a report on Thursday. Chardan Capital upgraded Definium Therapeutics to a “strong-buy” rating in a research note on Wednesday, November 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Definium Therapeutics in a report on Thursday, January 22nd. Finally, Royal Bank Of Canada raised their price objective on shares of Definium Therapeutics from $20.00 to $36.00 and gave the stock an “outperform” rating in a report on Friday, January 23rd. Four analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $35.22.

Definium Therapeutics Stock Down 2.1%

DFTX stock opened at $16.88 on Thursday. The company’s 50 day moving average price is $13.76 and its 200 day moving average price is $11.74. The firm has a market capitalization of $1.66 billion, a price-to-earnings ratio of -8.27 and a beta of 2.57. Definium Therapeutics has a fifty-two week low of $4.70 and a fifty-two week high of $18.12. The company has a debt-to-equity ratio of 0.31, a quick ratio of 3.30 and a current ratio of 3.30.

Definium Therapeutics (NASDAQ:DFTX) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.26). On average, equities research analysts anticipate that Definium Therapeutics will post -1.35 EPS for the current fiscal year.

Insider Transactions at Definium Therapeutics

In related news, insider Daniel Karlin sold 5,600 shares of the business’s stock in a transaction dated Friday, December 26th. The stock was sold at an average price of $13.15, for a total value of $73,640.00. Following the transaction, the insider owned 425,025 shares in the company, valued at $5,589,078.75. The trade was a 1.30% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Mark Sullivan sold 11,276 shares of the company’s stock in a transaction on Friday, December 26th. The stock was sold at an average price of $13.15, for a total transaction of $148,279.40. Following the transaction, the insider owned 282,576 shares of the company’s stock, valued at approximately $3,715,874.40. The trade was a 3.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 42,667 shares of company stock worth $561,071. Insiders own 2.26% of the company’s stock.

Institutional Trading of Definium Therapeutics

Several hedge funds have recently modified their holdings of the business. BIT Capital GmbH acquired a new stake in shares of Definium Therapeutics in the third quarter valued at about $26,000. Fifth Third Bancorp raised its stake in Definium Therapeutics by 5,593.2% in the 3rd quarter. Fifth Third Bancorp now owns 3,359 shares of the company’s stock valued at $40,000 after purchasing an additional 3,300 shares during the last quarter. Sound Income Strategies LLC purchased a new position in shares of Definium Therapeutics during the third quarter valued at approximately $46,000. Russell Investments Group Ltd. boosted its holdings in shares of Definium Therapeutics by 110.4% during the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after purchasing an additional 2,003 shares during the last quarter. Finally, CWM LLC boosted its stake in Definium Therapeutics by 67.4% in the 2nd quarter. CWM LLC now owns 4,459 shares of the company’s stock worth $29,000 after buying an additional 1,796 shares during the last quarter. 27.91% of the stock is owned by institutional investors and hedge funds.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.